University of Spontaneous CD4(+) and CD8(+) T-cell responses directed against cancer testis antigens are present in the peripheral blood of testicular cancer patients

Cancer/testis antigen (CTAg) expression is restricted to spermatogenic cells in an immune-privileged site within the testis. However, these proteins are expressed aber-rantly by malignant cells and T-cell responses against CTAgs develop in many cancer patients. We investigated the prevalence, magnitude and phenotype of CTAg-specific T cells in the blood of patients with testicular germ cell tumors (TGCTs). CD8 + and CD4 + T-cell responses against MAGE-A family antigens were present in 44% (20/45) of patients’ samples assayed by ex vivo IFN- γ ELISPOT. The presence of MAGE-specific CD8 + T cells was further determined following short-term in vitro expansion through the use of pMHC-I multimers containing known immunogenic peptides. Longitudinal analysis revealed that the frequency of MAGE-specific T cells decreased by 89% following orchidectomy suggesting that persistence of tumor antigen is required to sustain CTAg-specific T-cell immunity. Notably, this decrease correlated with a decline in the global effector/memory T-cell pool following treatment. Spontaneous T-cell immunity against CTAg proteins therefore develops in many patients with testicular cancer and may play an important role in the excellent clinical outcome of patients with this tumor subtype. two independent groups, a non-parametric Mann–Whitney test was performed. A Wilcoxon matched-pairs signed-rank test was used to compare non-parametric paired data. A linear regression was performed to assess the relationship between two variables. Spearman’s nonparametric test was used to determine correlations. Normal distribution was assessed using the D’Agostino & Pearson test, where appropriate. A p value < 0.05 was considered statistically significant.

[1]  M. Belvin,et al.  Is all cancer therapy immunotherapy? , 2015, Science Translational Medicine.

[2]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[3]  M. White,et al.  Degradation of AMPK by a Cancer-Specific Ubiquitin Ligase , 2015, Cell.

[4]  H. Moch,et al.  Cancer testis antigen expression in testicular germ cell tumorigenesis , 2014, Modern Pathology.

[5]  R. Schreiber,et al.  New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. , 2014, Current opinion in immunology.

[6]  E. Gostick,et al.  Immunodominance and functional alterations of tumor‐associated antigen‐specific CD8+ T‐cell responses in hepatocellular carcinoma , 2014, Hepatology.

[7]  P. Heuschmann,et al.  Boost and loss of immune responses against tumor-associated antigens in the course of pregnancy as a model for allogeneic immunotherapy. , 2013, Blood.

[8]  M. Evans,et al.  Decreased HPV-specific T cell responses and accumulation of immunosuppressive influences in oropharyngeal cancer patients following radical therapy , 2013, Cancer Immunology, Immunotherapy.

[9]  Yao-Tseng Chen,et al.  Chromosome X-encoded cancer/testis antigens show distinctive expression patterns in developing gonads and in testicular seminoma. , 2011, Human reproduction.

[10]  M. Itkin,et al.  Expansion of interferon-gamma-producing multifunctional CD4+ T-cells and dysfunctional CD8+ T-cells by glypican-3 peptide library in hepatocellular carcinoma patients. , 2011, Clinical immunology.

[11]  Yao-Tseng Chen,et al.  Cancer/testis (CT) antigens: Potential targets for immunotherapy , 2009, Cancer science.

[12]  A. S. Juncker,et al.  Analysis of gene expression profiles of microdissected cell populations indicates that testicular carcinoma in situ is an arrested gonocyte. , 2009, Cancer research.

[13]  P. Moss,et al.  Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma. , 2008, Blood.

[14]  Wei Liu,et al.  The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. , 2008, Cancer research.

[15]  P. Haaland,et al.  Functional T Cell Responses to Tumor Antigens in Breast Cancer Patients Have a Distinct Phenotype and Cytokine Signature1 , 2007, The Journal of Immunology.

[16]  J. Ku,et al.  Promoter hypomethylation and reactivation of MAGE-A1 and MAGE-A3 genes in colorectal cancer cell lines and cancer tissues. , 2006, World journal of gastroenterology.

[17]  J. Becker,et al.  Tumor infiltrating lymphocytes in seminoma lesions comprise clonally expanded cytotoxic T cells , 2006, International journal of cancer.

[18]  L. Looijenga,et al.  Testicular germ-cell tumours in a broader perspective , 2005, Nature Reviews Cancer.

[19]  P. Coulie,et al.  High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens , 2005, The Journal of experimental medicine.

[20]  Christian Schwager,et al.  Embryonic Stem Cell-Like Features of Testicular Carcinoma in Situ Revealed by Genome-Wide Gene Expression Profiling , 2004, Cancer Research.

[21]  B. Walker,et al.  Pervasive Influence of Hepatitis C Virus on the Phenotype of Antiviral CD8+ T Cells1 , 2004, The Journal of Immunology.

[22]  P. Klenerman,et al.  Population analysis of antiviral T cell responses using MHC class I‐peptide tetramers , 2003, Clinical and experimental immunology.

[23]  Hao Shen,et al.  Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory , 2003, Science.

[24]  Urs Christen,et al.  CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes , 2003, Nature.

[25]  Susan M. Kaech,et al.  Molecular and Functional Profiling of Memory CD8 T Cell Differentiation , 2002, Cell.

[26]  Yao-Tseng Chen,et al.  Cancer/testis antigens: an expanding family of targets for cancer immunotherapy , 2002, Immunological reviews.

[27]  J. Harty,et al.  Programmed contraction of CD8+ T cells after infection , 2002, Nature Immunology.

[28]  N. Rioux-Leclercq,et al.  The Cancer-Testis Gene, NY-ESO-1, Is Expressed in Normal Fetal and Adult Testes and in Spermatocytic Seminomas and Testicular Carcinoma In Situ , 2002, Laboratory Investigation.

[29]  P. Chomez,et al.  MAGE‐A4, a germ cell specific marker, is expressed differentially in testicular tumors , 2001, Cancer.

[30]  S. Mukherjee,et al.  Tumor Progression Despite Efficient Tumor Antigen Cross-Presentation and Effective “Arming” of Tumor Antigen-Specific CTL1 , 2001, The Journal of Immunology.

[31]  O. Ogawa,et al.  Expression patterns of cancer testis antigens in testicular germ cell tumors and adjacent testicular tissue. , 2001, The Journal of urology.

[32]  R. Grobholz,et al.  Expression of MAGE antigens and analysis of the inflammatory T-cell infiltrate in human seminoma , 2000, Urological Research.

[33]  O. Brændstrup,et al.  Immunopathology of in situ seminoma , 2000, International journal of experimental pathology.

[34]  J. Cheville,et al.  MAGE-1 and MAGE-3 tumor rejection antigens in human germ cell tumors. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[35]  H. Miyake,et al.  Expression of MAGE genes in testicular germ cell tumors. , 1999, Urology.

[36]  L. Old,et al.  Cancer Tumor antigens. , 1997, Current opinion in immunology.

[37]  W. Heath,et al.  Induction of a CD8+ Cytotoxic T Lymphocyte Response by Cross-priming Requires Cognate CD4+ T Cell Help , 1997, The Journal of experimental medicine.

[38]  P. Bruggen,et al.  Human tumor antigens recognized by T lymphocytes , 1996, The Journal of experimental medicine.

[39]  Per Capita,et al.  About the authors , 1995, Machine Vision and Applications.

[40]  Y. Tomita,et al.  Immunohistochemical detection of intercellular adhesion molecule-1 (ICAM-1) and major histocompatibility complex class I antigens in seminoma. , 1993, The Journal of urology.

[41]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[42]  Yao-Tseng Chen,et al.  Chromosome X-encoded Cancer/Testis antigens are less frequently expressed in non-seminomatous germ cell tumors than in seminomas. , 2013, Cancer immunity.

[43]  P. Haaland,et al.  Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature. , 2007, Journal of immunology.

[44]  N. Skakkebaek,et al.  Possible carcinoma-in-situ of the testis. , 1972, Lancet.

[45]  F. Burnet The concept of immunological surveillance. , 1970, Progress in experimental tumor research.